Tetraphase Pharmaceuticals Highlights Data at Upcoming American Society for Microbiology Microbe 2019 Annual Meeting

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that new data will be presented at the American Society for Microbiology (ASM) Microbe 2019 Annual Meeting, taking place June 20-24 in San Francisco. Presentations will include data on XERAVA^TM (eravacycline), a novel, fully synthetic fluorocycline approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of complicated intra-abdominal infections (cIAI), and TP-6076, a clinical-stage candidate in development to target multidrug-resistant infections.

The details for the presentations at ASM Microbe are as follows:

Poster title: Global In Vitro Surveillance of Eravacycline Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant Pathogens, Collected in 2017
Presenter: Sara Hwang, Pharm.D.
Track: Antimicrobial Agents and Resistance
Sub-track: AAR01 – Surveillance of Antimicrobial Resistance: Molecular Typing/Clinical and Molecular Epidemiology
Date and time: Friday, June 21 from 10:30 a.m. – 5:00 p.m. PT
Session type: Poster Presentation
Poster number: AAR-543

Poster title: Activity of Eravacycline and Comparators Against 15,887 Bacterial Pathogens Isolated From Patients Receiving Care in Canadian Hospitals: CANWARD 2014-2018
Presenter: George G. Zhanel, Pharm.D., Ph.D.
Track: Antimicrobial Agents and Resistance
Sub-track: AAR09 – Pharmacological Studies of Investigational Agents Pre-NDA (Phase 2/3)
Date and time: Saturday, June 22 from 10:30 a.m. – 5:00 p.m. PT
Session type: Poster Presentation
Poster number: AAR-790

Poster title: Multicenter Evaluation of Eravacycline MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative MIC Panels
Presenter: Jennifer Y. Chau, Ph.D.
Track: Clinical and Public Health Microbiology
Sub-track: CPHM02 – Antimicrobial Susceptibility Testing
Date and time: Sunday, June 23 from 10:30 a.m. – 4:00 p.m. PT
Session type: Poster Presentation
Poster number: CPHM-862

Poster title: First Comparative Evaluation of ETEST ERV bioMérieux With the CLSI Broth Microdilution Method for Eravacycline MIC Determination
Presenter: Edwige Pillon, bioMérieux S.A.; Marcy l’Etoile, France
Track: Clinical and Public Health Microbiology
Sub-track: CPHM02 – Antimicrobial Susceptibility Testing
Date and time: Sunday, June 23 from 10:30 a.m. – 4:00 p.m. PT
Session type: Poster Presentation
Poster number: CPHM-865

Poster title: Activity of Cefiderocol (CFDC), Ceftazidime-Avibactam (CZA), and Eravacycline (ERV) Against Carbapenem-Resistant (CR) E. coli Isolates From the U.S.: Clonal Background, Resistance Genes, and Co-Resistance